AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2020

Jun 4, 2020

30610_dirs_2020-06-04_687a639a-755b-4e69-ac83-19d773cf6ee1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-05-05

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-05	Common Stock	S	4770	$50.48	Disposed	0	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on September 26, 2019 and January 21, 2020.